Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Prometheus Biosciences, Inc. RXDX
$193.37
-$0.43 (-0.22%)
На 18:04, 12 мая 2023
-33.64%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
9286739205.00000000
-
week52high
197.83
-
week52low
21.50
-
Revenue
6809000
-
P/E TTM
-61
-
Beta
-0.59816200
-
EPS
-3.50000000
-
Last Dividend
0.00000000
-
Next Earnings Date
13 мая 2021 г. в 20:00
Описание компании
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 12 авг 2022 г. |
| Credit Suisse | Outperform | Outperform | 12 авг 2022 г. |
| Goldman Sachs | Buy | 20 июл 2022 г. | |
| Piper Sandler | Overweight | 10 июн 2022 г. | |
| Wells Fargo | Overweight | Overweight | 13 мая 2022 г. |
| Wells Fargo | Overweight | Overweight | 29 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 29 авг 2022 г. |
| RBC Capital | Outperform | Outperform | 04 окт 2022 г. |
| Oppenheimer | Outperform | Outperform | 04 окт 2022 г. |
| BTIG | Buy | Buy | 03 окт 2022 г. |
| Stifel | Buy | Buy | 01 ноя 2022 г. |
| RBC Capital | Outperform | Outperform | 08 дек 2022 г. |
| Oppenheimer | Outperform | Outperform | 08 дек 2022 г. |
| Credit Suisse | Outperform | Outperform | 08 дек 2022 г. |
| BTIG | Buy | Buy | 08 дек 2022 г. |
| Goldman Sachs | Buy | Buy | 31 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Marshall Keith W | D | 118040 | 5000 | 17 янв 2023 г. |
| Marshall Keith W | D | 9811 | 5000 | 17 янв 2023 г. |
| Marshall Keith W | A | 14811 | 5000 | 17 янв 2023 г. |
| McKenna Mark C. | D | 333633 | 25000 | 17 янв 2023 г. |
| McKenna Mark C. | D | 55144 | 25000 | 17 янв 2023 г. |
| McKenna Mark C. | A | 80144 | 25000 | 17 янв 2023 г. |
| Marshall Keith W | A | 12920 | 12920 | 16 дек 2022 г. |
| Stenhouse Mark | A | 34085 | 34085 | 09 дек 2022 г. |
| Stenhouse Mark | A | 26442 | 9811 | 09 дек 2022 г. |
| Marshall Keith W | A | 34085 | 34085 | 09 дек 2022 г. |
Новостная лента
5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
24/7 Wall Street
19 янв 2023 г. в 22:53
Mid-cap stocks are proving to be an attractive investment option over the past few years.
These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022
24/7 Wall Street
09 янв 2023 г. в 22:50
Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 08:30
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, MD, Chief Medical Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 3:45 p.m. PST.
Prometheus Biosciences CEO on the company's ability to raise capital, get FDA approval
CNBC Television
09 дек 2022 г. в 19:27
Cramer spoke with Prometheus Biosciences CEO Mark McKenna on Friday.
Is Prometheus Biosciences a Good Stock to Buy Right Now?
The Motley Fool
09 дек 2022 г. в 05:32
This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead.